Quality of Awakening and Impact on Cognitive Function After Administration of Sugammadex in Robotic Radical Cystectomy
NCT ID: NCT02454504
Last Updated: 2018-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2015-03-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the investigators study was to assess whether the reversal with sugammadex after intraoperative continuous infusion of rocuronium, can improve the quality of awakening.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium
NCT03328312
Neuromuscular Blockade During Transurethral Resection of Bladder Cancer
NCT03039543
Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)
NCT00559468
Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)
NCT00298831
Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)
NCT00758485
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sugammadex
this arm will receive sugammadex at the end of the surgery
sugammadex
neostigmine
this arm will receive neostigmine at the end of the surgery
Neostigmine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sugammadex
Neostigmine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients underwent robotic cystectomy
Exclusion Criteria
* BMI ≥ 30
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regina Elena Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ester Forastiere
Dr
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Regina Elena Cancer Institute
Rome, RM, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
307.CI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.